Gong Jing, Jin Bo, Shang Liang, Liu Ning
Department of Geriatrics, The First Hospital of China Medical University, Shenyang, China.
Department of Medical Oncology, Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, Liaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, China.
Front Mol Biosci. 2021 Nov 1;8:714053. doi: 10.3389/fmolb.2021.714053. eCollection 2021.
Within the endocrine system, thyroid cancer (THCA) is the most typical malignant tumor. Tumor-infiltrating immune cells play vital roles in tumor progression, recurrence, metastasis as well as response to immunotherapy. However, THCA's immune infiltrative landscape is still not clarified. Therefore, we utilized two statistical algorithms to investigate the immune cell infiltration (ICI) landscape of 505 THCA samples and defined three ICI immune subtypes. The ICI scores were calculated using principal-component analysis. Increased tumor mutation burden (TMB) and immune-related signaling pathways were associated to a high ICI score. The high ICI score group indicated a relatively longer overall survival (OS) than the low ICI score group. Most immune checkpoint-related and immune activation-related genes were considerably upregulated in the ICI high group, which indicates stronger immunogenicity and a greater likelihood of benefiting from immunotherapy. In two cohort studies of patients receiving immunotherapy, high-ICI-score group showed notable therapeutic effects and clinical advantages compared to those with lower ICI scores. These results demonstrate that ICI score acts as an effective prognostic indicator and predictor of response to immunotherapy.
在内分泌系统中,甲状腺癌(THCA)是最典型的恶性肿瘤。肿瘤浸润免疫细胞在肿瘤进展、复发、转移以及免疫治疗反应中起着至关重要的作用。然而,THCA的免疫浸润情况仍未明确。因此,我们利用两种统计算法研究了505例THCA样本的免疫细胞浸润(ICI)情况,并定义了三种ICI免疫亚型。ICI评分通过主成分分析计算得出。肿瘤突变负荷(TMB)增加和免疫相关信号通路与高ICI评分相关。高ICI评分组的总生存期(OS)相对长于低ICI评分组。大多数免疫检查点相关基因和免疫激活相关基因在ICI高分组中显著上调,这表明免疫原性更强,从免疫治疗中获益的可能性更大。在两项接受免疫治疗患者的队列研究中,高ICI评分组与低ICI评分组相比显示出显著的治疗效果和临床优势。这些结果表明,ICI评分是一种有效的预后指标和免疫治疗反应预测指标。